A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.

The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans ...

The complaint argues Kennedy’s actions to remove the COVID vaccine from the CDC's immunization schedule for pregnant people ...

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health. New drugs for obesity ...